| pubmed-article:2068087 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2068087 | lifeskim:mentions | umls-concept:C0019707 | lld:lifeskim |
| pubmed-article:2068087 | lifeskim:mentions | umls-concept:C0017968 | lld:lifeskim |
| pubmed-article:2068087 | lifeskim:mentions | umls-concept:C0020960 | lld:lifeskim |
| pubmed-article:2068087 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:2068087 | lifeskim:mentions | umls-concept:C1446680 | lld:lifeskim |
| pubmed-article:2068087 | lifeskim:mentions | umls-concept:C0086597 | lld:lifeskim |
| pubmed-article:2068087 | lifeskim:mentions | umls-concept:C1511636 | lld:lifeskim |
| pubmed-article:2068087 | lifeskim:mentions | umls-concept:C0597551 | lld:lifeskim |
| pubmed-article:2068087 | pubmed:issue | 14 | lld:pubmed |
| pubmed-article:2068087 | pubmed:dateCreated | 1991-8-14 | lld:pubmed |
| pubmed-article:2068087 | pubmed:abstractText | Twenty-five 13- to 35-amino-acid-long peptides representing regions of human immunodeficiency virus type 2 (HIV-2), strain SBL6669, envelope proteins were evaluated for their immunogenic activity in guinea pigs. The peptides were selected to provide homologous representation of sites in the HIV-1 envelope proteins that were previously documented to have a particular immunogenic importance. A number of the HIV-2 peptides were found to be capable of inducing strain SBL6669 neutralizing and antibody-dependent cellular cytotoxicity (ADCC) antibodies. Two overlapping peptides covering amino acids 311-337 representing the central and C-terminal part of the variable third (V3) region, terminology according to Modrow et al. [Modrow, S., Hahn, B., Shaw, G. M., Gallo, R. C., Wong-Staal, F. & Wolf, H. (1987) J. Virol. 61, 570-578], showed the most pronounced capacity to induce neutralizing antibodies. One of the peptides (amino acids 318-337) also induced antibodies mediating ADCC. Two additional regions in the large glycoprotein, gp125, containing linear sites reacting with neutralizing antibodies were identified (amino acids, 119-137 and 472-509). The transmembrane protein, gp36, of HIV-2 harbored two regions of importance for induction of neutralizing antibodies (amino acids 595-614 and 714-729). ADCC activity was induced by two additional gp125-specific peptides (amino acids 291-311 and 446-461). Thus, except for the single V3-specific site there was no correlation between linear immunogenic sites stimulating neutralizing antibody and ADCC activity. These findings pave the way for development of synthetic vaccines against HIV-2 and possibly also simian immunodeficiency virus infections. The capacity of such a product to induce protective immunity can be evaluated in macaque monkeys. | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2068087 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2068087 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2068087 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2068087 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:2068087 | pubmed:issn | 0027-8424 | lld:pubmed |
| pubmed-article:2068087 | pubmed:author | pubmed-author:NorrbyEE | lld:pubmed |
| pubmed-article:2068087 | pubmed:author | pubmed-author:UtterGG | lld:pubmed |
| pubmed-article:2068087 | pubmed:author | pubmed-author:BernardiDD | lld:pubmed |
| pubmed-article:2068087 | pubmed:author | pubmed-author:ThorstenssonR... | lld:pubmed |
| pubmed-article:2068087 | pubmed:author | pubmed-author:BrolidenKK | lld:pubmed |
| pubmed-article:2068087 | pubmed:author | pubmed-author:ChiodiFF | lld:pubmed |
| pubmed-article:2068087 | pubmed:author | pubmed-author:BjörlingEE | lld:pubmed |
| pubmed-article:2068087 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2068087 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:2068087 | pubmed:volume | 88 | lld:pubmed |
| pubmed-article:2068087 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2068087 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2068087 | pubmed:pagination | 6082-6 | lld:pubmed |
| pubmed-article:2068087 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:meshHeading | pubmed-meshheading:2068087-... | lld:pubmed |
| pubmed-article:2068087 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:2068087 | pubmed:articleTitle | Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity. | lld:pubmed |
| pubmed-article:2068087 | pubmed:affiliation | Department of Virology, Karolinska Institute, Stockholm, Sweden. | lld:pubmed |
